Literature DB >> 1660221

Prevalence of antibodies to hepatitis C virus in the hemodialysis unit.

H H Lin1, C C Huang, I S Sheen, D Y Lin, Y F Liaw.   

Abstract

An enzyme immunoassay was used to detect antibodies to hepatitis C virus (anti-HCV) in 261 patients and 69 staff members of a hemodialysis unit. The prevalence of anti-HCV was 46.7% in patients and 2.9% in staff members (p less than 0.001). The prevalence of anti-HCV increased significantly with increasing duration of hemodialysis (p less than 0.001), but was not related to age, sex, history of blood transfusion, status of hepatitis B or hepatitis A virus infection, or serum ALT. Patients with hepatitis episode increased with increasing duration of hemodialysis and showed a significantly higher prevalence of anti-HCV than those without (63.1 vs. 34.7%, p less than 0.001). The prevalence of anti-HCV in patients with hepatitis also increased with increasing duration of hemodialysis (p = 0.05). Thus, HCV appears to be the major cause of hepatitis in hemodialysis patients. Besides strict infection control measures, further studies are needed to determine the mode of HCV infection and its prevention in the hemodialysis unit.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660221     DOI: 10.1159/000168302

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  3 in total

1.  Application of kushenin on patients with chronic hepatitis C after renal transplantation.

Authors:  Yang Li; Wu-jun Xue; Ping Fan; Chen-guang Ding; Huan-jin Song; Xiao-ming Ding; Xin-shun Feng
Journal:  Chin J Integr Med       Date:  2008-10-14       Impact factor: 1.978

2.  Hepatitis C infection in children and adolescents on haemodialysis and after renal transplant.

Authors:  M Greco; K Cristiano; G Leozappa; M Rapicetta; G Rizzoni
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

3.  Hepatitis B, delta and human immunodeficiency virus infections among Omani patients with renal diseases: A seroprevalence study.

Authors:  S S Al-Dhahry; P N Aghanashinikar; H A Al-Marhuby; M R Buhl; A S Daar; M K Al-Hasani
Journal:  Ann Saudi Med       Date:  1994-07       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.